ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
Huachansu triggers mitochondrial apoptosis and ER stress to inhibit hepatocellular carcinoma progression.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Huachansu, derived from the dried skin glands of the Chinese toad (Bufo bufo gargarizans), has been used in traditional Chinese medicine for its anti-tumor properties, particularly in hepatocellular carcinoma (HCC). However, its molecular mechanisms remain unclear. This study investigates Huachansu's therapeutic potential by focusing on mitochondrial apoptosis and endoplasmic reticulum (ER) stress pathways. In vitro studies on HepG2 cells revealed that Huachansu (48-96 mg/mL for 24 h) disrupted mitochondrial function by elevating reactive oxygen species (ROS) generation (~ 83% and ~ 208% increase at 48 and 96 mg/mL, respectively) and reducing membrane potential. Molecular analyses showed upregulated pro-apoptotic Bax and ER stress effector CHOP alongside downregulated anti-apoptotic Bcl-2 and caspase family proteins, indicating PERK-ATF4 pathway activation. In vivo investigations using orthotopic and xenograft HCC mouse models demonstrated significant tumor volume (~ 25% at 2 g/kg and ~ 39% at 4 g/kg) and weight reduction with Huachansu treatment (2-4 g/kg/day, oral gavage for 18-21 days). Hepatic function improvements were evidenced by decreased serum ALT, AST, and LDH levels alongside increased superoxide dismutase (SOD) activity. Histopathological analyses confirmed reduced tumor progression and organ toxicity, while inflammatory cytokine profiling revealed diminished pro-inflammatory mediators. Mechanistically, Huachansu activated ER stress markers (PERK, ATF4) in tumor tissues without inducing systemic toxicity. These findings demonstrate that Huachansu exerts potent anticancer effects in HCC through concurrent induction of mitochondrial damage and ER stress activation. This study provides a mechanistic basis for Huachansu's traditional use and highlights its potential as a promising therapeutic agent for HCC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.